News
TRDA
7.45
+4.16%
0.30
Weekly Report: what happened at TRDA last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at TRDA last week (0608-0612)?
Weekly Report · 06/15 09:18
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 06/10 21:05
Entrada Therapeutics Stockholders Approve Directors and Equity Plans
TipRanks · 06/10 20:52
Entrada Therapeutics shareholders approved amendments to 2021 incentive plan, employee stock purchase plan
PUBT · 06/10 20:07
Entrada Therapeutics Price Target Cut to $17.00/Share From $20.00 by Guggenheim
Dow Jones · 06/08 14:28
Entrada Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 06/08 14:28
Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17
Benzinga · 06/08 14:18
Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim
TipRanks · 06/08 11:22
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)
TipRanks · 06/08 11:21
Weekly Report: what happened at TRDA last week (0601-0605)?
Weekly Report · 06/08 09:17
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 06/05 21:06
Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)
TipRanks · 06/03 12:44
Analysts’ Top Healthcare Picks: Zenas BioPharma, Inc. (ZBIO), Entrada Therapeutics Inc (TRDA)
TipRanks · 06/03 11:10
Entrada Therapeutics posts corporate deck outlining Duchenne muscular dystrophy, DM1 clinical pipeline milestones
PUBT · 06/02 11:23
Entrada Advances Duchenne Muscular Dystrophy Drug to Higher Dose Cohort, Safety Review Clears Next Stage of Clinical Trial
Benzinga · 06/02 11:17
Entrada Therapeutics clears 10 mg/kg Cohort 2 start in ELEVATE-45-201 DMD trial for ENTR-601-45
PUBT · 06/02 11:05
ENTRADA THERAPEUTICS - ON TRACK TO REPORT ELEVATE-45-201 COHORT 1 DATA IN MID-2026
Reuters · 06/02 11:04
Entrada Therapeutics grants 18,600 inducement RSUs to new hires under 2025 equity plan
PUBT · 06/01 20:30
ENTRADA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/01 20:30
More
Webull provides a variety of real-time TRDA stock news. You can receive the latest news about Entrada Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.